Wong C L
Eur J Pharmacol. 1987 Mar 17;135(2):219-23. doi: 10.1016/0014-2999(87)90614-5.
Nalbuphine given subcutaneously (s.c.) inhibited gastrointestinal transit in a dose-dependent manner. Prior s.c. administration of naloxone hydrochloride suppressed the inhibitory effect of nalbuphine on gastrointestinal transit. Naloxone methobromide (naloxone MB), a quaternary compound, was also effective in antagonising this effect of nalbuphine but was less effective than naloxone hydrochloride. Furthermore, prior s.c. administration of Mr 2266 also antagonised the gastrointestinal transit inhibitory action of nalbuphine. When given centrally, either intracerebroventricularly (i.c.v.) or intracisternally (i.c.), naloxone hydrochloride was ineffective in antagonising s.c. nalbuphine. Similar findings were observed with centrally administered Mr 2266. In addition, i.c. nalbuphine had a minimal effect on gastrointestinal transit while i.c.v. nalbuphine only caused slight inhibition of gastrointestinal transit. It was concluded that nalbuphine inhibits gastrointestinal transit mainly through peripheral opiate receptors.
皮下注射纳布啡以剂量依赖的方式抑制胃肠蠕动。预先皮下注射盐酸纳洛酮可抑制纳布啡对胃肠蠕动的抑制作用。季铵化合物甲溴化纳洛酮(纳洛酮MB)在拮抗纳布啡的这种作用方面也有效,但效果不如盐酸纳洛酮。此外,预先皮下注射Mr 2266也可拮抗纳布啡对胃肠蠕动的抑制作用。当脑室内(i.c.v.)或脑池内(i.c.)中枢给药时,盐酸纳洛酮在拮抗皮下注射纳布啡方面无效。对中枢给药的Mr 2266也观察到类似的结果。此外,脑池内注射纳布啡对胃肠蠕动的影响最小,而脑室内注射纳布啡仅引起胃肠蠕动的轻微抑制。得出的结论是,纳布啡主要通过外周阿片受体抑制胃肠蠕动。